Supernus Pharmaceuticals
SUPN
235 hedge funds and large institutions have $1.59B invested in Supernus Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 90 increasing their positions, 67 reducing their positions, and 28 closing their positions.
57% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 28
34% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 67
10% more capital invested
Capital invested by funds: $1.45B → $1.59B (+$139M)
5% more funds holding
Funds holding: 223 → 235 (+12)
1.52% more ownership
Funds ownership: 102.33% → 103.85% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
28% less call options, than puts
Call options by funds: $2.84M | Put options by funds: $3.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$19.1M |
| 2 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
+$10.3M |
| 3 |
LCG
Lisanti Capital Growth
New York
|
+$9.24M |
| 4 |
AC
Armistice Capital
New York
|
+$7.16M |
| 5 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$6.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$12.4M |
| 2 |
Millennium Management
New York
|
-$9.89M |
| 3 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$8.93M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$8.72M |
| 5 |
Renaissance Technologies
New York
|
-$4.54M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
251
Penserra Capital Management
Orinda,
California
| – | -$32K | -1,215 | Closed |
|
|
CA
252
Clearstead Advisors
Cleveland,
Ohio
| – | -$17K | -626 | Closed |
|
|
SMA
253
Sage Mountain Advisors
Atlanta,
Georgia
| – | -$15K | -574 | Closed |
|
|
LWM
254
Liberty Wealth Management
Oakland,
California
| – | -$9K | -326 | Closed |
|
|
CFD
255
Creative Financial Designs
Kokomo,
Indiana
| – | -$8K | -297 | Closed |
|
|
MAM
256
Meeder Asset Management
Dublin,
Ohio
| – | -$8K | -292 | Closed |
|
|
JG
257
Jefferies Group
New York
| – | -$2.67K | -100 | Closed |
|
|
CFA
258
Carroll Financial Associates
Charlotte,
North Carolina
| – | -$1K | -56 | Closed |
|
|
DWP
259
Destiny Wealth Partners
Tavares,
Florida
| – | -$1K | -29 | Closed |
|
260
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$182 | +6 | New |
|
|
CFB
261
Cullen/Frost Bankers
San Antonio,
Texas
| – | +$334 | +11 | New |
|
|
SCA
262
Snowden Capital Advisors
New York
| – | +$758 | +25 | New |
|
SUPN Hedge Fund Activity: Q4 2021 in Review
235 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2021, worth a combined $1.59B — up 9.6% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new SUPN positions and 28 closed out — a net gain of 16 holders — while 90 added to existing stakes and 67 trimmed.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $19.1M. The largest seller was BlackRock, cutting an estimated $12.4M.
- 235 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2021, up from 223 in Q3 2021.
- Funds reported $1.59B of Supernus Pharmaceuticals stock for Q4 2021, up 9.6% quarter-over-quarter.
- 44 funds opened new Supernus Pharmaceuticals positions in Q4 2021 and 28 closed out, a net change of +16 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2021 was Polar Capital Holdings, an estimated $19.1M added.
- The largest Supernus Pharmaceuticals seller in Q4 2021 was BlackRock, an estimated $12.4M sold.
Based on aggregated 13F filings for Q4 2021.